A recent metanalyses [41] evidenced CIS patients to have higher levels of CSF Chi3L1 compared to healthy controls, suggesting an overexpression from the early phase of the disease and highlighting its potential as a prognostic biomarker. The gene discussed is CHI3L1; the disease is in situ carcinoma.